| Overview |
| bs-3204R-APC-Cy5.5 |
| IRS1(Tyr896) Polyclonal Antibody, APC-Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Others |
| Human, Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications |
| APC-Cy5.5 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human IRS1 around the phosphorylation site of Tyr896 [GE(p-Y)VN] |
| Tyr896 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3667 |
| Cell membrane |
| p-IRS1; IRS1Tyr896; HIRS 1; HIRS1; Insulin Receptor Substrate 1; IRS-1; IRS 1; IRS1 |
| Insulin receptor substrates (IRS) are responsible for several insulin related activities, such as glucose homeostasis, cell growth, cell transformation, apoptosis and insulin signal transduction. Serine/threonine phosphorylation of IRS1 has been demonstrated to be a negative regulator of insulin signaling and is responsible for its degradation, although IRS1 degradation pathways are not well understood. IRS1 has also been shown to be constitutively activated in cancers such as breast cancer, Wilm's tumors, and adrenal cortical carcinomas, thus making IRS1 phosphorylation and subsequent degradation an attractive therapeutic target. To date there have been four subtypes identified: IRS1, 2, 3 and 4, with IRS1 being widely expressed. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz